Orthocell (ASX:OCC) raised AU$17 million via the placing of 28,333,333 shares at AU$0.60 apiece to launch collagen nerve wrap Remplir in the US and to drive further growth.
The issue price represented a 12% discount to the 10-day volume weighted average price, according to a Friday filing with the Australian bourse.
Shares under the placement will be allotted on Oct. 31, the filing said.
Orthocell said it remains on schedule to release top-line results from its Remplir US market authorization study and submit its US market authorization application in the fourth quarter, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.